APLS
Price:
$34.94
Market Cap:
$4.35B
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glome...[Read more]
Industry
Biotechnology
IPO Date
2017-11-09
Stock Exchange
NASDAQ
Ticker
APLS
According to Apellis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 4.42B. This represents a change of -22.18% compared to the average of 5.68B of the last 4 quarters.
The mean historical Enterprise Value of Apellis Pharmaceuticals, Inc. over the last ten years is 2.27B. The current 4.42B Enterprise Value has changed 19.37% with respect to the historical average. Over the past ten years (40 quarters), APLS's Enterprise Value was at its highest in in the June 2023 quarter at 10.36B. The Enterprise Value was at its lowest in in the June 2016 quarter at 0.
Average
2.27B
Median
1.14B
Minimum
151.75M
Maximum
6.86B
Discovering the peaks and valleys of Apellis Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 274.48%
Maximum Annual Enterprise Value = 6.86B
Minimum Annual Increase = -33.73%
Minimum Annual Enterprise Value = 151.75M
Year | Enterprise Value | Change |
---|---|---|
2023 | 6.86B | 35.97% |
2022 | 5.05B | 41.74% |
2021 | 3.56B | -13.37% |
2020 | 4.11B | 140.36% |
2019 | 1.71B | 201.00% |
2018 | 568.26M | 274.48% |
2017 | 151.75M | -33.73% |
2016 | 228.98M | 5.11% |
2015 | 217.84M | -9.32% |
2014 | 240.22M | -3.56% |
The current Enterprise Value of Apellis Pharmaceuticals, Inc. (APLS) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
5.16B
5-year avg
4.26B
10-year avg
2.27B
Apellis Pharmaceuticals, Inc.’s Enterprise Value is less than Prometheus Biosciences, Inc. (9.30B), greater than Akero Therapeutics, Inc. (1.88B), greater than Immunovant, Inc. (3.74B), less than Madrigal Pharmaceuticals, Inc. (6.67B), greater than Day One Biopharmaceuticals, Inc. (954.38M), greater than Mirati Therapeutics, Inc. (3.91B), greater than Amylyx Pharmaceuticals, Inc. (273.81M), greater than Terns Pharmaceuticals, Inc. (283.27M), greater than X4 Pharmaceuticals, Inc. (66.58M), greater than Inozyme Pharma, Inc. (196.96M), greater than Mereo BioPharma Group plc (501.64M), less than Blueprint Medicines Corporation (6.45B), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Acumen Pharmaceuticals, Inc. (130.78M),
Company | Enterprise Value | Market cap |
---|---|---|
9.30B | $9.56B | |
1.88B | $2.16B | |
3.74B | $4.22B | |
6.67B | $6.78B | |
954.38M | $1.37B | |
3.91B | $4.12B | |
273.81M | $343.08M | |
283.27M | $552.10M | |
66.58M | $85.78M | |
196.96M | $174.74M | |
501.64M | $581.03M | |
6.45B | $6.06B | |
8.24B | $8.19B | |
130.78M | $133.98M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Apellis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Apellis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Apellis Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Apellis Pharmaceuticals, Inc. (APLS)?
What is the 3-year average Enterprise Value for Apellis Pharmaceuticals, Inc. (APLS)?
What is the 5-year average Enterprise Value for Apellis Pharmaceuticals, Inc. (APLS)?
How does the current Enterprise Value for Apellis Pharmaceuticals, Inc. (APLS) compare to its historical average?